Welcome to our dedicated page for Healthcare Triangle SEC filings (Ticker: HCTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Healthcare Triangle, Inc. (HCTI) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered tools to help interpret complex documents. As an emerging growth company listed on The Nasdaq Stock Market LLC, Healthcare Triangle files a variety of reports that shed light on its healthcare IT and digital health operations, capital structure, and governance.
For investors analyzing HCTI, Form 10-K annual reports and Form 10-Q quarterly reports are central sources for understanding its healthcare information technology business, including cloud and data platforms (CloudEz™ and DataEz™), security and compliance services, data lifecycle management, interoperability work, and clinical and business performance optimization. These filings also describe risk factors, segment information, and accounting policies relevant to its software, managed services, and platform offerings.
Healthcare Triangle’s Form 8-K current reports are particularly important given the company’s active financing and acquisition strategy. Recent 8-Ks disclose:
- Material definitive agreements for senior unsecured convertible promissory notes under a Securities Purchase Agreement.
- Warrant inducement agreements and related new warrant issuances, including changes to exercise prices and registration commitments.
- Reverse stock split actions intended to address Nasdaq bid price requirements.
- Asset transfer and acquisition-related amendments involving Niyama Healthcare, Inc. and Ezovion Solutions Private Limited.
- Nasdaq compliance communications regarding listing rules and shareholder approval requirements.
Proxy statements on Schedule 14A detail proposals for electing directors, ratifying auditors, and obtaining shareholder approval for future securities issuances under Nasdaq Listing Rule 5635(d). These documents also explain voting rights, meeting logistics, and aspects of the company’s governance framework.
On this page, Stock Titan surfaces real-time updates from EDGAR and applies AI-powered summaries to key filings. Users can quickly see the main terms of financing agreements, the structure of warrant and note offerings, and the implications of reverse stock splits or listing determinations. Where applicable, insider ownership and voting power information disclosed in proxy materials can be reviewed alongside other filings, while Form 4 insider trading reports, when available, provide additional context on management and major holder transactions.
By combining raw SEC documents with AI-generated explanations, this filings hub helps investors, analysts, and researchers navigate Healthcare Triangle’s regulatory history and understand how its capital markets activity, acquisitions, and governance decisions support its healthcare IT and AI-driven digital health strategy.
Healthcare Triangle, Inc. (HCTI) has filed a pre-effective amendment to register 1,458,118 shares of common stock for resale by existing security holders. These shares consist of 1,429,528 shares issuable upon exercise of inducement warrants and 28,590 shares issuable upon exercise of advisor warrants granted in connection with an October 2025 warrant inducement transaction. The company is not selling shares itself under this prospectus and will not receive proceeds from any resale, though it has already received $2.85 million from the prior warrant exercise and may receive additional cash if the new warrants are exercised at their $3.00 exercise price. If all common warrants are exercised, common stock outstanding would be 5,873,303 shares. The filing also highlights HCTI’s cloud, data, and AI-driven healthcare IT platforms and notes that adding freely tradable shares could pressure the stock price and dilute existing holders.
Healthcare Triangle, Inc. (HCTI) entered into a Sales Agreement with Spartan Capital Securities, LLC to sell shares of its common stock from time to time through an at-the-market offering program. The shares will be issued under an existing shelf registration statement on Form S-3, using a prospectus supplement dated November 18, 2025, with an aggregate market value of common stock currently eligible for sale of $20,000,000.
Spartan will act as sales agent and receive a 3.0% commission on the gross sales price of shares sold through it. Healthcare Triangle will control sale parameters such as number of shares, timing, daily limits, and minimum prices, and may suspend sales at any time. The agreement ends when all shares under the prospectus supplement are sold or if the agreement is otherwise terminated.
Healthcare Triangle, Inc. is launching an at-the-market offering of up to $20,000,000 of its common stock through Spartan Capital Securities as sales agent. Shares may be sold from time to time on Nasdaq under the symbol HCTI, with Spartan earning a 3% commission on gross sales.
The company plans to use any net proceeds for general corporate purposes, including potential acquisitions and working capital. An illustrative scenario assumes selling 9,569,377 shares at $2.09 per share, which would raise $20 million and increase as-adjusted net tangible book value to $1.48 per share, while creating $0.61 per-share dilution for new investors.
Recent actions include a 1-for-249 reverse stock split that reduced outstanding shares to 5,831,816, a warrant inducement that generated approximately $2.85 million in gross proceeds, and a $5.7 million asset and equity acquisition from Niyama Healthcare to expand mental health and hospital information systems capabilities.
Healthcare Triangle, Inc. (HCTI) has called a virtual-only special meeting of stockholders on November 28, 2025 to vote on a single key item. Stockholders are being asked to approve, for purposes of Nasdaq Listing Rule 5635(d), future issuances of the Company’s securities in an aggregate amount of up to $70 million during the period from November 14, 2025 until February 28, 2026, as long as each issuance meets specified Nasdaq parameters.
Nasdaq Rule 5635(d) generally requires stockholder approval when a company issues 20% or more of its common stock (or voting power) in certain non‑public transactions at prices below a defined minimum. Approval of this proposal would satisfy that requirement for qualifying transactions completed within the stated period. The Company notes that any such future issuances under these parameters would have a dilutive effect on existing stockholders’ ownership and voting power over time. Only stockholders of record as of November 12, 2025 are entitled to vote, and the Board unanimously recommends voting “FOR” the proposal.
Healthcare Triangle, Inc. reported Q3 results with net revenue of $3,489 (up 45% year over year) and a net loss of $1,906. For the nine months, revenue was $10,752 (up 13%), with a net loss of $4,973. Segment mix shifted toward Software Services, while Managed Services declined.
Liquidity and the balance sheet changed markedly. Cash and cash equivalents were $1,629 as of September 30, 2025. Net cash used in operating activities was $9,689, offset by $12,587 of net financing cash inflows primarily from equity issuance. Total assets rose to $13,838 from $1,961 at year‑end, reflecting the June 16 acquisition of Niyama Healthcare/Ezovion (purchase price $5,700, including cash, 1,388,041 restricted shares valued at $3,000, and up to $1,200 earn‑out). Stockholders’ equity improved to $8,726 from a deficit.
The company effected a 1‑for‑249 reverse stock split on August 1, 2025. Short‑term borrowing under the Seacoast facility was $1,530, and convertible notes were eliminated through conversion and repayment. As of November 13, 2025, 7,261,344 common shares were outstanding.
Healthcare Triangle, Inc. reported results of its November 7, 2025 annual meeting. Shareholders elected four directors for one-year terms and ratified SRCO Professional Corporation as independent auditor for 2025.
Participation was strong: 21,423,722 shares (approximately 82.80% of 25,873,304 entitled shares) were represented, including common stock and Series A Super Voting Preferred Stock.
Director votes: Sujatha Ramesh For 20,253,344, Withheld 7,524; Dave Rosa For 20,171,021, Withheld 89,847; Jainal Bhuiyan For 20,244,585, Withheld 16,283; Ron McClurg For 20,250,055, Withheld 10,813. Each director vote recorded 1,162,854 broker non-votes.
Auditor ratification: For 21,275,588, Against 57,036, Abstain 91,098, with 0 broker non-votes.
Healthcare Triangle, Inc. (HCTI) called a virtual‑only special meeting for December 16, 2025 to seek stockholder approval, for purposes of Nasdaq Listing Rule 5635(d), of potential issuances of securities completed from the meeting date for three months in an aggregate amount up to $[50] million, if each issuance meets stated Nasdaq Parameters.
The company lists parameters and a latest closing date no later than February [●], 2026, and states the purpose is to provide additional working capital. The filing notes that any such issuances will dilute existing stockholders over time, including their voting power. Only stockholders of record as of November [●], 2025 may vote, and the meeting will be accessible via live webcast only.
Healthcare Triangle, Inc. filed an S-3 registering the resale of up to 1,458,118 shares of common stock issuable upon exercise of previously issued warrants, including 1,429,528 shares tied to new Inducement Warrants and 28,590 shares tied to Inducement Advisor Warrants. The company is not selling shares in this registration and will receive no proceeds from any resale; it may receive cash only if warrants are exercised.
The Inducement Warrants carry a $3.00 per-share exercise price and become exercisable after stockholder approval for issuances above 19.99% of outstanding common stock, with a five-year term and a 4.99% (or 9.99% at holder election) beneficial ownership cap. The filing allows selling stockholders to use customary methods to dispose of shares. Examples of registered amounts per holder include Robert Forster 286,862 and Bigger Capital Fund, LP 191,241. The company states warrant exercise proceeds, if any, would be used for working capital and general corporate purposes.
Healthcare Triangle (HCTI) called its 2025 Annual Meeting for November 7, 2025 at 10:00 a.m. Pacific Time, to be held virtually. Stockholders will vote to elect four directors and to ratify SRCO Professional Corporation as the independent registered public accounting firm for the fiscal year ending December 31, 2025. The Board unanimously recommends voting FOR all nominees and FOR auditor ratification.
Only stockholders of record at the close of business on September 29, 2025 may vote. Registration to attend is required by November 5, 2025 at 11:59 p.m. Eastern Time. Nominees are Dave Rosa, Sujatha Ramesh, Ronald McClurg, and Jainal Bhuiyan.
SRCO has served as auditor since April 2025; prior reports by M&K CPAS, PLLC contained no adverse opinions or modifications. As context, Suresh Venkatachari holds Series A Super Voting Preferred Shares representing 77.11% of voting power as of October 15, 2025. Shares outstanding were 5,873,304 common and 20,000 Series A Super Voting Preferred as of October 15, 2025.
Healthcare Triangle, Inc. (HCTI) reported that a holder of approximately 81.82% of its voting power approved, by written consent, the issuance of 1,388,041 restricted common shares to Niyama Healthcare, Inc. as partial consideration for an acquisition. The deal also includes $1.5 million in cash (with $1.2 million paid at closing and $300,000 payable later) and up to $1.2 million in earn-out payments tied to first‑year performance targets to be agreed within 90 days of closing.
The shares are being issued under Nasdaq Listing Rule 5635(a)(2). The action becomes effective 20 calendar days after mailing of the information statement. Shares outstanding were 5,831,829 as of September 19, 2025; this is a baseline figure, not the amount being issued.
HCTI acquired the seller’s cloud and technology domain assets and 100% of Ezovion Solutions Private Limited, a hospital information systems SaaS provider in Chennai, India. No proxy is being solicited, and no further shareholder action is required.